Revolutionizing human medicine with molecular glues

DISCOVER MORE

Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues towards the treatment of human disease.

Our technology builds upon the discoveries of our Scientific Founders, who provided the seminal observations on molecular glues and have explored them for over 30 years.

shapes image
shapes image
shapes image

THE SCIENCE

TrueGlues are compounds that induce cooperative interactions between multiple proteins

Targeted protein degradation has revealed the potential of molecular glues to treat human disease. Historically, TrueGlues have been found by chance; Magnet Biomedicine is changing that. The Magnet team is leveraging human genetics and proteomic data to select protein pairs for the development of monovalent molecular glues, altering the function of targets by degradation, stabilization, or inhibition. Magnet will pioneer the discovery of novel molecular glue medicines for the treatment of cancer, cardiovascular disease, and immune disorders. Rationally designed molecular glues will restrict drug effects to disease-relevant tissues, induce biological synergy, and target undruggable proteins.

OUR TECHNOLOGY

Building upon recent advances in proteomics, screening, and bioinformatics, we believe the time is now to execute on this long-standing goal of rational molecular glue discovery

Our TrueGlue discovery platform combines state-of-the-art screening technologies utilizing diverse chemical libraries and human-biology-driven target selection. Our process integrates diverse streams of in-house and external data to discover and exploit novel molecular glue mechanisms of action.  Magnet’s TrueGlue technology can be applied in an indication-agnostic manner to discover molecular glues with a wide range of target modulation, drug-like properties, and selectivity.  

OUR PEOPLE

Brian Safina
Brian Safina, Ph.D.
President & Chief Scientific Officer
View Bio
close
Brian Safina, Ph.D.
Brian Safina, Ph.D.
President & Chief Scientific Officer
Brian Safina, Ph.D. is President and Chief Scientific Officer, at Magnet Biomedicine. Brian has over 20 years of drug discovery experience in the pharmaceutical and biotechnology industries.  Prior to joining Magnet, Brian served as Senior Vice President, Discovery Research at Bolt Biotherapeutics, a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics.  Prior to joining Bolt, Brian served in roles of increasing responsibility at Genentech, a member of the Roche Group, in Discovery Chemistry. Over the course of his career, he has contributed to the discovery and development of multiple clinical candidates across a range of modalities and disease areas. He has published more than 34 papers and is co-inventor on more than 50 granted patents and patent applications. Brian received his B.S. in Chemistry from Loyola Marymount University, and holds a Ph.D. in organic chemistry from the University of California, San Diego.
Bret Williams
Bret Williams, Ph.D.
Vice President of Biology
View Bio
close
Bret Williams, Ph.D.
Bret Williams, Ph.D.
Vice President of Biology
Bret Williams, Ph.D. is Vice President of Biology at Magnet Biomedicine. Bret has more than 12 years of drug discovery experience, working in both pharmaceutical and biotech settings. Prior to joining Magnet, Bret was a Senior Director at Relay Therapeutics, leading target selection and lead generation activities for both oncology and genetic disease projects. During his tenure at Relay, Bret lead or co-lead several programs, including Relay’s first clinical candidate, the SHP2 inhibitor RLY-1971. Prior to Relay, Bret served in roles of increasing responsibility within the Oncology Therapeutic Area at Sanofi. Bret received his Ph.D. from the University of Wisconsin in Cellular and Molecular Biology and completed postdoctoral work as a Howard Hughes Medical Institute fellow at the Massachusetts Institute of Technology. Bret has published more than 12 peer-reviewed articles, including manuscripts in Science and Cell during his career.
Matthew Hayward
Matthew Hayward, Ph.D.
Vice President of Drug Discovery
View Bio
close
Matthew Hayward, Ph.D.
Matthew Hayward, Ph.D.
Vice President of Drug Discovery
Matthew Hayward, Ph.D. is Vice President of Drug Discovery at Magnet Biomedicine. Matt has over 26 years of experience in the pharmaceutical industry. Prior to joining Magnet, Matt spent 26 years as a medicinal chemist at Pfizer Inc. During his time there, he contributed to the discovery of 8 clinical candidates in the fields of inflammation, neuroscience, immunology, and oncology, penned 30 peer reviewed publications, and was an inventor on 26 patents. At Pfizer, Matt led the successful Scripps Research collaboration with Professor Benjamin Cravatt and his lab for over a decade, helping to advance the Cravatt lab’s industry leading chemoproteomics platform. Matt is currently the CFO for the Medicinal and Bioorganic Chemistry Foundation, a not-for-profit group established for the arrangement and sponsorship of international conferences, symposia, and educational programs dedicated to the advancement of bioorganic, synthetic, and medicinal chemistry. The foundation runs the popular biennial MBCF conference in Steamboat, Colorado. Matt received his B.A. from Connecticut College, a Ph.D. in organic chemistry from Yale University, and was also an NIH postdoctoral fellow at Harvard University.
Jennifer Franklin
Jennifer Franklin
Vice President of Administration & Operations
View Bio
close
Jennifer Franklin
Jennifer Franklin
Vice President of Administration & Operations
Jennifer Franklin is Vice President of Administration and Operations at Magnet Biomedicine. Jennifer has 12 years of experience with Fidelity Investments Tax-Exempt Services and PwC Healthcare Advisory as well as 10 years of biotech experience with Editas Medicine and Cedilla Therapeutics with the opportunity to join both companies at a pre-Series A stage. Prior to joining Magnet, Jennifer served as Chief of Staff at Cedilla Therapeutics. Jennifer holds a BS in Business Administration and Economics from Framingham State University.
Kristina Burow
Kristina Burow
Managing Director at ARCH Venture Partners
View Bio
close
Kristina Burow
Kristina Burow
Managing Director at ARCH Venture Partners
Kristina Burow is focused on the creation and development of biotechnology, pharmaceutical and health tech companies. Since joining ARCH in 2002, she has risen from Associate to Managing Director and has played a significant role in the growth of ARCH’s life sciences portfolio, including multiple public companies exceeding billion-dollar valuations. Prior to joining ARCH, Kristina was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spinouts from GNF. Kristina holds an M.B.A. from the University of Chicago, an M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Thomas Cahill
Thomas Cahill, M.D., Ph.D.
Founder and Managing Partner at Newpath Partners
View Bio
close
Thomas Cahill, M.D., Ph.D.
Thomas Cahill, M.D., Ph.D.
Founder and Managing Partner at Newpath Partners
Tom Cahill, MD, PhD, is the founder and managing partner of Newpath Partners, a Boston-based life science venture firm with a mission to translate groundbreaking scientific discoveries into treatments for patients with a broad range of diseases. Newpath creates and builds most of its portfolio companies at the earliest stage of development, working closely with successful entrepreneurial scientists to align their interests with investors, management teams, and employees.
Benjamin F. Cravatt, Ph.D.
Founder
View Bio
close
Benjamin F. Cravatt, Ph.D.
Benjamin F. Cravatt, Ph.D.
Founder
Benjamin F. Cravatt, Ph.D. is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics (acquired by Bayer AG). His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He was awarded the 2022 Wolf Prize in Chemistry.
David Spiegel
David A. Spiegel, M.D., Ph.D.
Founder
Michael Rosbash
Michael Rosbash, Ph.D.
Founder
View Bio
close
Michael Rosbash, Ph.D.
Michael Rosbash, Ph.D.
Founder
Michael Rosbash, Ph.D., the Peter Gruber Endowed Chair in Neuroscience, is a Professor of Biology and a Howard Hughes Medical Institute Investigator at Brandeis University known for his discoveries concerning circadian rhythms, the cyclical 24-hour period of biological activity that drives daily behavioral patterns. He was awarded the 2017 Nobel Prize in Physiology or Medicine.
Richa Saxena, Ph.D.
Founder
View Bio
close
Richa Saxena, Ph.D.
Richa Saxena, Ph.D.
Founder
Richa Saxena, Ph.D. is an Associate Professor of Anesthesia at Harvard Medical School; an Assistant in Genetics at the Center for Genomic Medicine Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital; and the Director of Genetics of Sleep and Circadian Research Program in Sleep Epidemiology, Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women’s Hospital. She is also an Associate Member in the Medical and Population Genetics Program at the Broad Institute.
Stuart Schreiber, Ph.D.
Founder
View Bio
close
Stuart Schreiber, Ph.D.
Stuart Schreiber, Ph.D.
Founder
Stuart Schreiber, Ph.D. is a co-Founder of the Broad Institute since 2003 and the Morris Loeb Professor in the Department of Chemistry and Chemical Biology at Harvard University. He is an elected member of the National Academy of Sciences, National Academy of Medicine, and the American Academy of Arts and Sciences. He is the recipient of numerous awards, most recently the Wolf Prize in Chemistry. He is the co-Founder of numerous successful public biotechnology companies including Vertex Pharmaceuticals, Ariad Pharmaceuticals, H3 Biomedicine, and Forma Therapeutics, with a combined valuation of over $85B.
Xiao Chen
Xiao Chen, Ph.D.
Biology
YiQun Chen
YiQun Chen
Biology
Jessica Gasser
Jessica Gasser, Ph.D.
Biology
Shubhroz Gill
Shubhroz Gill, Ph.D.
Biology
Bruce Hua
Bruce Hua, Ph.D.
Chemistry
Liam Hudson
Liam Hudson, Ph.D.
Chemistry
Chueh-Ling Kuo
Chueh-Ling Kuo, Ph.D.
Biomolecular Discovery
Igor Levchenko
Igor Levchenko, Ph.D.
Protein Production
Alyssa Lutservitz
Alyssa Lutservitz, MS
Informatics
Ashish Maurya
Ashish Maurya, Ph.D.
Biology
Andrew Reidenbach
Andrew Reidenbach, Ph.D.
Biomolecular Discovery
David Rhee
David Rhee, Ph.D.
Proteomics
Tiffany Tsang
Tiffany Tsang, Ph.D.
Biology
Hsin-Lan Wen, Ph.D.
Biology

OUR INVESTORS

shapes image
shapes image

CAREERS

Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our Founders.

We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.

Click the job openings to learn more.

Scientist/Senior Scientist, Proteomics
close
Scientist/Senior Scientist, Proteomics

Magnet Biomedicine

Founded by Ben Cravatt, Michael Rosbash, Richa Saxena, David Spiegel, and Stuart Schreiber and backed by leading venture capital partners, we are rapidly growing our team and looking for creative, collaborative, and action-oriented individuals to help drive our molecular glue discovery platform.

The Magnet Biomedicine platform integrates innovative screening technologies, human biology driven protein selection, and state-of-the-art proteomics methods to enable the rational discovery of molecular glues.

Scientist/Senior Scientist, Proteomics

We are seeking a scientist with a strong background in experimental and computational proteomics to join our growing team at Magnet Biomedicine. This is an exciting opportunity to contribute to the discovery of molecular glue therapeutics, while helping to push the boundaries of what is possible as we advance our drug discovery proteomics platform.

The ideal candidate will provide expertise in the development, optimization, and analysis of quantitative proteomics experiments, as well as hands-on experience with the maintenance, quality control, and troubleshooting of instrumentation. Interest and experience with the development of proteomics focused computational workflows and integration with other data types is highly desired.

Magnet offers competitive pay and benefits including medical, dental, and vision insurance, incentive plan, 401(k) program, and a generous holiday and PTO policy. This is a full-time position in Cambridge, MA.

Key Responsibilities:

  • The development and optimization of robust quantitative proteomic workflows.
  • Maintenance, quality control, and troubleshooting of instrumentation.
  • Identification, evaluation, and implementation of new methods.
  • Data management, analysis, and integration with other platform resources.

Qualifications:

  • Ph.D. in Analytical Chemistry, Biochemistry, Chemical Biology, or a related field with 3+ years of experience in quantitative proteomics.
  • Broad experience with proteomics sample preparation.
  • Extensive hands-on knowledge of instrument maintenance and QC.
  • Experience with quantitative proteomics methods (SRM/PRM, TMT, SILAC, DIA, Label-free)
  • Proficiency with search and analysis software (MaxQuant, PD, Fragpipe, Skyline, etc.)
  • Proficiency with downstream statistical analysis (Perseus, R, Python, MSstats, etc).
  • Experience with protein-protein interaction methods, PTM workflows, chemoproteomics, and thermal proteome profiling is a plus (IP-MS, proximity labeling, XL-MS, TPP/PISA)
  • Cell culture experience is a plus.

Scientist/Senior Scientist, Compound Management
close
Scientist/Senior Scientist, Compound Management

About the job

Magnet Biomedicine

Founded by Stuart Schreiber, Michael Rosbash, Ben Cravatt, Richa Saxena, and David Spiegel and backed by leading venture capital partners, we are rapidly growing our team and looking for creative, collaborative, and action-oriented individuals to help drive our molecular glue discovery platform. The Magnet Biomedicine platform integrates innovative screening technologies, human biology driven protein selection, and state-of-the-art proteomics methods to enable the rational discovery of molecular glues.

Scientist/Senior Scientist, Compound Management

­­We are seeking a scientist with a strong background in compound management and laboratory automation to join our growing team. This is an exciting opportunity to contribute to the discovery of molecular glue therapeutics through building a highly integrated internal compound management and high throughput chemistry platform.

Key responsibilities

  • Lead all compound management functions including inventory of small molecule screening collections and building blocks, biological materials, sample tracking, distribution, and data management.
  • Fulfill dry and solution-based compound sample requests for internal and external partners.
  • Troubleshoot liquid handling platforms and analytical instrumentation.
  • Development of automation systems for solution manipulations.
  • Integrate with medicinal chemistry and analytical sciences to ensure optimal program progression and data quality.

Qualifications

  • Seven (7) years of relevant post-degree work experience is required with a Bachelor’s degree.
  • Five (5) years of relevant post-degree work experience is required with a Master’s degree.
  • Three (3) years of relevant post-degree work experience is required with a PhD.
  • Considerable experience with internalized compound management of small molecules (Hamilton or Azenta experience preferred).
  • Proficiency with use and basic maintenance of analytical equipment, specifically LCMS.
  • Proficiency with LIMS integration, compound registration and inventory management software (Dotmatics preferred).
  • Familiar with laboratory operations and management.
  • Excellent organization and communication skills.
  • Must be flexible and responsive to changing priorities.
  • Enthusiasm for taking on new projects and grow with a growing company.
  • Commitment to maintain the highest standards of safety and compliance.
APPLY NOW
VISIT US ON LINKEDIN